How Does the FDA's Drug Supply Chain Security Act Affect Your Business?

The Drug Supply Chain Security Act (DSCSA), enacted in 2013, is the FDA's framework for the safety and integrity of the pharmaceutical supply chain in the United States. It requires prescription drugs to be traceable at the package level throughout the supply chain. The goal is to keep counterfeit, stolen, contaminated, or harmful drugs out of the U.S. supply, and to detect and remove them quickly when they do appear.

This post covers the key DSCSA requirements, the 2025 to 2026 enforcement timeline, where the industry stands, and how quality teams track compliance signals across their supply chain.

Key Requirements of DSCSA

The DSCSA sets out five core requirements for stakeholders in the prescription drug supply chain.

Serialization

Each package of prescription drugs must carry a unique identifier, typically a 2D barcode, to enable tracking and tracing.

Transaction Information, Transaction History, and Transaction Statement

These documents (TI, TH, TS) must accompany each drug shipment and provide a detailed record of the drug's path through the supply chain.

Verification

Trading partners must have systems to confirm the legitimacy of drug products.

Detection and Response

Each entity must have processes to identify and react to suspect or illegitimate drugs.

Product Tracing

Businesses must be able to trace drugs back through the supply chain to the manufacturer.

Atlas

See what the FDA knows about your next investigator.

30 minutes with the founder. No pitch deck.

See it live

Compliance Deadlines and Enforcement

The FDA set a phased enforcement timeline for DSCSA compliance:

• Manufacturers and repackagers: May 27, 2025
• Wholesale distributors: August 27, 2025
• Dispensers with 26 or more full-time employees: November 27, 2025
• Small dispensers (25 or fewer full-time employees): exempt until November 27, 2026

As of May 27, 2025, manufacturers and repackagers are no longer exempt and must fully comply with all DSCSA requirements. Wholesale distributors are next, with their exemption ending August 27, 2025.

Industry Readiness

Industry surveys show steady progress in DSCSA readiness:

• By June 2025, 98.5% of distributors reported receiving complete serialized data from their suppliers.
• Among pharmacies, 39% reported receiving complete serialized data from 80 to 100% of their suppliers by June 2025, up from 24% in June 2024.

The progress is real, but smaller dispensers and some regional distributors still face gaps.

How Atlas Helps You Monitor Supply Chain Compliance Signals

DSCSA is about traceability. Atlas is about what happens when one of your suppliers or external manufacturers gets inspected, receives a 483, or gets hit with an import alert. Supply chain monitoring in Atlas lets you:

• Upload your supplier and external manufacturer list in bulk.
• Get alerts by email or WhatsApp when any supplier or external manufacturer gets inspected, receives a 483, or gets a warning letter.
• Search historical 483s, EIRs, and warning letters for any of your suppliers across 700,000+ FDA inspections since 2010.

If your supplier gets a 483, you see it on Atlas before they tell you. That window is what gives you time to qualify an alternative.